Íò²©Ë®¾§¹¬

QIN Li£¬ZHANG Haitao

( Cardiovaseular Second Department, Pingdingshan Second People's Hospital, Pingdingshan 467000, China)

Objective To observe the clinical effect of dabigatran in the treatment of hypertrophicAbstractcardiomyopathy ( HCM) with atrial fibrillation ( AF). Methods 121 patients with HCM eombined with AFwere selected and randomly divided into the contral group and observation group using a digital tablemethod. Both groups underwent radiofrequency ablation treatment, while the control group had 60 patientswho were received conventional anticoagulant therapy as an adjuvant surgery. The observation group had 6lpatients who were received dabigatran as an adjuvant surgery. The changes in platelet activity andcoagulation funetion before and after treatment were compared between the two groups, as well as the oecurrenee of cardiovascular adverse events and drug-related side reactions during the follow-up period.Results After treatment, the observation group's ¦Â-'TG, granular membrane protein CD62P, CD63 werelower than those of control group , while activated partial thromboplastin time ( APT'T ), prothrombin time( P'T) , thrombin time ('T'T) were higher than those of control group ( P<0.05 ); during the follow-upperiod, the incidence of cardiovascular adverse events and adverse reactions in observation group werelower than those in control group, with statistically significant differenees ( P < 0.05 ). ConclusionDabigatran assisted radiofrequency ablation can effectively inhibit platelet aetivity and improve coagulationfunetion in patients with HCM and AF, and has positive significanee in reducing of cardiovaseular adverseevents and drug adverse reactions.

Keywords : dabigatran ; hypertrophic cardiomyopathy; atrial fibrillation ; anticoagulant therapy

£Ä£Ï£É:£±£°.£±£¹£²£¹£¶/£ê.£ã£î£ë£é.£±£°£°£¸£­£²£´£°£¹.£²£°£²£´£­£°£±£­£°£±£³

PDFdownload£ºclick to download